FINASTERIDE 0.25%

FINASTERIDE 0.25%

€0,00
Skip to product information
FINASTERIDE 0.25%
Research Formulation • Topical Delivery System

FINASTERIDE 0.25%

Topical Research Solution
CAS No. 98319-26-7
Format 0.25% w/v
Volume 50 mL
Access request-only

Single-compound, solvent-based topical research formulation developed for localized, non-clinical androgen receptor interaction studies.

Submit Formulation Request

Prefer email communication?
Request this formulation via our consultation form.

Request-only supply. No instant checkout. All formulation requests are reviewed before fulfilment.

Technical Data
Chemical Identification
Chemical NameN-(1,1-dimethylethyl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide
SynonymsFinasteride MK-906 Proscar Propecia
Molecular FormulaC23H36N2O2
Molecular Weight372.55 g/mol
Compound ClassSelective 5α-reductase type II inhibitor
Purity≥98%
InChIKeyDBEPLOCGEIEOCV-WSBQPABSSA-N
Physicochemical Characteristics
AppearanceClear to slightly opalescent, colorless to faint yellow solution.
Formulation TypeTopical Solution
Delivery SystemSolvent-based topical formulation
Solubility ContextMulti-solvent carrier architecture utilized to support a stable 0.25% w/v Finasteride concentration.
Water ContentNo added water. Water-free solvent architecture selected to support compound integrity and formulation consistency.
StorageStore tightly closed in a cool, dry, dark environment.
StabilityStability may vary depending on exposure to heat, light, oxygen, and prolonged environmental stress.
Documentation & Analytical Data
Analytical StandardResearch-grade analytical reference
Research ClassificationNon-clinical research formulation
Laboratory StatusResearch-use material
Batch DocumentationInternal batch documentation and formulation records maintained for research traceability purposes.
Documentation AvailabilityCOA / SDS / Batch Records available upon request depending on batch and formulation configuration.
TraceabilityBatch-level internal reference architecture maintained for controlled formulation tracking.
Research Documentation
Formulation Specification

Concentration system: 0.25% w/v

Equivalent concentration: 2.5 mg/mL

Total active content: 125 mg per 50 mL

Vehicle system: Ethanol 96% (Ph. Eur.) / Propylene Glycol (Ph. Eur.) / Diethylene Glycol Monoethyl Ether — Transcutol® P (Ph. Eur.)

Solvent ratio: 60 / 12.5 / 27.5

Formulation architecture: Multi-solvent topical carrier system designed to support compound solubility, formulation consistency, and controlled surface application modeling.

Water content: No added water

Formulation complexity: Single-compound system

Research Context

Finasteride is a selective 5α-reductase type II inhibitor investigated within non-clinical research models involving localized androgen pathway modulation and tissue-level enzymatic interaction behavior.

In topical research contexts, Finasteride formulations are commonly evaluated as surface-applied compounds where localized delivery behavior, carrier-system compatibility, and controlled androgen-related pathway interaction are relevant experimental parameters.

Experimental focus is generally directed toward localized biochemical signaling models, formulation dispersion behavior, and controlled surface-level interaction architecture within non-clinical laboratory environments.

This GeneTherica formulation is positioned as a research-grade topical solution for controlled, non-clinical laboratory use. It is not supplied for therapeutic, diagnostic, cosmetic, or human application.

Storage & Handling

Storage range: 2–8°C preferred; 15–25°C acceptable for short-term controlled handling.

Storage conditions: Store tightly closed in a cool, dry, dark environment.

Light sensitivity: Protect from direct sunlight and UV exposure.

Temperature stability: Avoid freezing and excessive heat exposure.

Air exposure: Minimize prolonged exposure to air.

Closure requirement: Keep container tightly sealed when not in use.

Stability context: Storage conditions are intended to support solvent balance, formulation consistency, and compound integrity during controlled non-clinical handling.

Research Use Notice

Supplied exclusively for laboratory research and analytical applications.

Not intended for therapeutic, cosmetic, veterinary, food, household, diagnostic, or human application.

Handling should occur within qualified non-clinical research environments only.

Vehicle System
Multi-Solvent Carrier Architecture
Ethanol 96% Ph. Eur.
Propylene Glycol Ph. Eur.
Transcutol® P Ph. Eur.
Solvent Ratio 60 / 12.5 / 27.5
Research Use Notice
GeneTherica products are supplied for research use only. Products are not medicines, cosmetics, or approved therapeutic agents. Information provided is for technical and research-context identification only and does not constitute medical, clinical, or treatment guidance.
Documentation Availability
COA / SDS / Batch Records
Available upon request depending on batch and formulation configuration.
Research-Grade Quality
Manufactured under defined quality standards for consistent research performance.
Topical Delivery System
Solvent-based formulation designed for localized and targeted research applications.
Transparency
Full documentation and traceability for every research batch.
Secure & Confidential
Your research and inquiries are handled with complete confidentiality.

Overview

Finasteride is a selective 5α-reductase type II inhibitor investigated within controlled research environments involving localized androgen pathway modulation and tissue-level enzymatic interaction models.

Within topical research frameworks, Finasteride formulations are primarily examined for their ability to influence localized dihydrotestosterone (DHT) conversion pathways within surface-confined application environments.

Experimental focus is generally directed toward localized biochemical signaling behavior, carrier-system interaction, and controlled tissue-level delivery architecture associated with androgen-related biological response pathways.

Research applications emphasize surface-confined topical delivery systems designed to support localized formulation behavior while minimizing broader systemic exposure variables within non-clinical study models.

This formulation is presented as a research-grade topical solution intended exclusively for scientific, analytical, and laboratory-based investigation under appropriately controlled handling conditions.

Laboratory liquid surface
Scientific liquid wave
Laboratory glassware
GeneTherica Documentation Infrastructure

Research Documentation & Technical Systems

Documentation architecture associated with the RU58841 topical research system, including batch-level analytical reference, solvent-system infrastructure, physicochemical handling orientation, and controlled safety documentation access.
Research Infrastructure
Technical Documentation Layer
GeneTherica documentation systems are structured around controlled formulation architecture, analytical reference context, solvent-system engineering, and batch-oriented research documentation.
Research Overview →
Physicochemical Orientation
Documentation emphasizes solvent compatibility, evaporation behavior, crystallization prevention, and controlled carrier architecture.
Batch-Level Structure
Technical references may include batch identifiers, analytical specification context, and raw material traceability layers.
Research Context
Documentation infrastructure is intended for controlled non-clinical research orientation and laboratory identification purposes.
Controlled Systems
Access to certain documentation layers may depend on compound configuration, formulation type, and request evaluation.